| Oxycodone Hydrochloride and Acetaminophen | Mallinckrodt | ||
| 325;7.5 mg: Tablet, Extended Release, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
| None |
Less Than 5
|
||
| None | None | ||
| Management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options are ineffective, not tolerated or would otherwise be inadequate | |||
|
Yes
| |||
| Xartemis XR | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ****** | ********* ** **** *** | ********* ** **** *** | ********* ** **** *** | ********* ** **** *** | ********* ** **** *** | ********* ** **** *** | ********* ** **** *** | ********* ** **** *** | ********* ** **** *** | ********* ** **** *** | ********* ** **** *** | *** ********* (***** ******) |
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* ********* **** ****** **** **** ********** **** ******* ** *** ***** **************** ***** | ******* ********* ********-******* ****** ***** ********** ************ ** * ***-****** ********* *** ** ****** ********* | ******* ********* ********-******* ****** ***** ********** ************ ** * ***-****** ********* *** ** ****** ********* | ******* ********* ********-******* ****** ***** ********** ************ ** * ***-****** ********* *** ** ****** ********* | ******* ** ********* ********** ***** ****** ************** ************ ********** ********** | *********** *********** ********** ********* *** ************* *** ***** ***** *** ******** ******** ** ********* | ******* ********* ********-******* ****** ***** ********** ************ ** * ***-****** ********* *** ** ****** ********* | ******* ********* ******** ******* ************** ************ | ******* ** ********* ********** ***** ****** ************** ************ ********** ********** | *********** *********** ********** ********* *** ************* *** ***** ***** *** ******** ******** ** ********* | ************** ************ *** ******** ******* ** ********* *** ************* ********* ** * ***** ***** *** ********* ****** ** ********* | *********** *********** ********** ********* *** ************* *** ***** ***** *** ******** ******** ** ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** ****** | ** \ ** | -**- | ********* ** **** *** | **** | ** *** **, **** |
| ******* | *** \ ********* | *** **, **** | ******* | ********* ******** | ******* *** **** *** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|